Q3 2025 EPS Estimates for Pfizer Inc. Increased by Analyst (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Zacks Research lifted their Q3 2025 earnings per share estimates for shares of Pfizer in a report released on Wednesday, June 26th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will earn $0.73 per share for the quarter, up from their previous estimate of $0.72. The consensus estimate for Pfizer’s current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pfizer’s FY2025 earnings at $2.61 EPS.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the company posted $1.23 EPS. The firm’s revenue was down 19.5% on a year-over-year basis.

A number of other equities analysts have also recently issued reports on the company. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley increased their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, June 26th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $35.54.

Pfizer Trading Down 1.4 %

Pfizer stock opened at $27.83 on Monday. The business has a 50 day moving average price of $27.93 and a two-hundred day moving average price of $27.70. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The stock has a market cap of $157.70 billion, a price-to-earnings ratio of -464.76, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. Pfizer has a 12 month low of $25.20 and a 12 month high of $37.80.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.04%. Pfizer’s payout ratio is presently -2,799.53%.

Institutional Trading of Pfizer

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ironvine Capital Partners LLC increased its holdings in Pfizer by 2.1% in the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after purchasing an additional 353 shares during the period. Advisor OS LLC increased its holdings in Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 365 shares during the period. Safeguard Investment Advisory Group LLC grew its holdings in Pfizer by 3.9% during the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 371 shares during the period. Lantz Financial LLC grew its holdings in Pfizer by 1.3% during the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 381 shares during the period. Finally, Wellington Shields Capital Management LLC grew its holdings in Pfizer by 1.3% during the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 385 shares during the period. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.